Product Description
Afacifenacin is being developed by Sumitomo Dainippon Pharma (formerly Dainippon Sumitomo Pharma) and Sunovion Pharmaceuticals as an orally administered therapy for overactive bladder and nocturia. Afacifenacin is a new antimuscarinic that possesses the dual pharmacological actions of non-selective muscarinic receptor antagonist and inhibition of the bladder afferent pathway through sodium-channel blockade. (Sourced from: https://drugs.ncats.io/drug/XQU62QZ74P)
Mechanisms of Action: Sodium Channel Blocker
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Dainippon Sumitomo Pharma America
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Overactive Bladder
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| SMP-986 phase 2 proof of concept in patients with OABS | P2 |
Completed |
Overactive Bladder |
2008-06-05 |
|
| OABS | P2 |
Completed |
Overactive Bladder |
2008-06-01 |
|
| JapicCTI-101261 | P2 |
Completed |
Overactive Bladder |
None |